Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1538-1540

  Prebet, Thomas ^a,b   Charbonnier, Aude ^a,b   Gelsi Boyer, Véronique ^a,b   Mozziconacci, Marie Joelle ^a,b   Blaise, Didier ^a,b   Vey, Norbert ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DRUG TREATMENT FAILURE; ERYTHROCYTE; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE;

AZACITIDINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84879340255     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.744455     Document Type: Letter

References (15)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
2. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
3. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010;116:1485-1494.
4. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011;29:3322-3327.
5. Prebet T, Gore SD, Thepot S, et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012;157:764-766.
6. Prebet T, Thepot S, Gore SD, et al. Outcome of patients with low risk myelodysplasia after azacitidine treatment failure. Haematologica 2013;98:e18-e19.
7. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557. (Pubitemid 40204668)
8. Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk 2012; 12: 341-344.
9. A des L, B oehrer S, P rebet T, et al. E fficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009;113:3947-3952.
10. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010;28:2253-2258.
11. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108 : 419-425. (Pubitemid 44061337)
12. Sekeres MA, O ' Keefe C, List AF, et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higherrisk myelodysplastic syndromes. Am J Hematol 2011;86:102-103.
13. S ugimoto Y, S ekeres M A, M akishima H, et al. C ytogenetic and molecular predictors of response in patients with myeloid malignancies without del [5q] treated with lenalidomide. J Hematol Oncol 2012;5:4.
14. J adersten M, S aft L, S mith A, et al. T P53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011;29:1971-1979.
15. S ekeres M A, G undacker H, L ancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 2011;118:523-528.